Aptevo Therapeutics Inc APVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise for $3.0 Million Gross Proceeds
Aptevo Therapeutics Announces Exercise of Existing Warrants for $3.0 Million Gross Proceeds
Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors
Aptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AML
Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Trading Information
- Previous Close Price
- $0.41
- Day Range
- $0.39–0.42
- 52-Week Range
- $0.38–25.56
- Bid/Ask
- $0.40 / $0.42
- Shares Outstanding
- 3.46M
- Market Cap
- $854,013.63
- Volume/Avg
- 149,398 / 130,362
Key Statistics
- Price/Earnings (Normalized)
- 0.00
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 33
Valuation
Metric | APVO |
|---|---|
Price/Earnings (Normalized) | 0.00 |
Price/Book Value | 0.28 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
APVO
Financial Strength
Metric | APVO |
|---|---|
Quick Ratio | 1.28 |
Current Ratio | 1.50 |
Interest Coverage | — |
Quick Ratio
APVO
Profitability
Metric | APVO |
|---|---|
Return on Assets (Normalized) | −123.76% |
Return on Equity (Normalized) | −224.21% |
Return on Invested Capital (Normalized) | −162.78% |
Return on Assets
APVO
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|Wl%BjZz | LOCK|?M&% | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#lvY<bL | LOCK|mT@b | $95B | |||
| Moderna Inc MRNA | LOCK|HX&sqw | LOCK|tYc | $79B | |||
| argenx SE ADR ARGX | LOCK|<M!P?z | LOCK|PZ^ | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!MmN@w | LOCK|Bx | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|S$L>B@hB | LOCK|@rlyN | $30B | |||
| Incyte Corp INCY | LOCK|KlF?>%? | LOCK|d$! | $23B | |||
| BioNTech SE ADR BNTX | LOCK|>b#bG%! | LOCK|b@H | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$W$CFV | LOCK|NN<% | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|WYGNc#H | LOCK|@tP | $15B |